Who are ABT-335 and simvastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ABT-335 plus rosuvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-335-and-simvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ABT-335 and simvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABT-335 and simvastatin (ABT-335 and simvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate + statin combination. Area: Cardiovascular.

phase 3 Fibrate + statin combination PPARα (ABT-335); HMG-CoA reductase (simvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ABT-335 and simvastatin (ABT-335 and simvastatin) — Abbott. ABT-335 (fenofibrate) combined with simvastatin works by reducing triglycerides and LDL cholesterol through dual lipid-lowering pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-335 and simvastatin TARGET	ABT-335 and simvastatin	Abbott	phase 3	Fibrate + statin combination	PPARα (ABT-335); HMG-CoA reductase (simvastatin)
ABT-335 plus rosuvastatin	ABT-335 plus rosuvastatin	AstraZeneca	phase 3	Fibrate + statin combination	PPARα (ABT-335); HMG-CoA reductase (rosuvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate + statin combination class)

Abbott · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-335 and simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-335-and-simvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab